PAI Life Sciences Inc.
Seattle, WA Doing business as PAI Life Sciences Inc.
- UEI
- MSMLUCM9DRT6
- CAGE
- 47SX4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
-
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) Primary
- 325412 Pharmaceutical Preparation Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541380 Testing Laboratories and Services
- 541690 Other Scientific and Technical Consulting Services
- 541713 Research and Development in Nanotechnology
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration date
- Physical address
- 1551 Eastlake Ave E #250, Seattle, WA 98102, USA
- Website
- pailifesciences.com
- Founded
- 2004
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, hematoshield - project summary… | National Institute of Allergy and Infectious Diseases | $295,386 | |
| Evaluation of a next generation schistoshield vaccine - abstract schistosomiasis is a major parasitic disease which… | National Institute of Allergy and Infectious Diseases | $600,000 | |
| Late stage adjuvant mimics based on TLR4 agonists | National Institute of Allergy and Infectious Diseases | $597,953 | |
| Adjuvanted recombinant candidates to prime / boost covid-19 RNA vaccines | Office of Financial Resources | $243,000 | |
| Developing a screen for new adjuvants to enhance RNA vaccines | National Institute of Allergy and Infectious Diseases | $511,601 |
About PAI Life Sciences Inc.
PAI Life Sciences Inc. is a self-certified small disadvantaged business that specializes in vaccine and adjuvant development for infectious diseases. The company has been registered to receive federal awards since 2005 and has a history of securing both contracts and grants from U.S. government agencies, particularly in the field of biomedical research. PAI Life Sciences focuses on developing innovative solutions for global health challenges, with a particular emphasis on neglected tropical diseases and emerging infectious threats.
Through federal contracts, PAI Life Sciences has engaged in advanced research and development projects for the National Institute of Allergy and Infectious Diseases (NIAID). The company was awarded a $597,953 definitive contract to develop late-stage adjuvant mimics based on toll-like receptor 4 agonists, contributing to NIAID's program for enhancing vaccine efficacy. This contract was designated as a total small business set-aside. Additionally, PAI Life Sciences secured a $2,961,685 Cost Plus Fixed Fee contract under the SBIR Phase II program to develop a prophylactic vaccine against onchocerciasis (river blindness). For this project, the company collaborated with Thomas Jefferson University and New York Blood Center, Inc. as subcontractors to conduct murine efficacy studies, develop potency assays, and assess safety and immunogenicity in non-human primates.
PAI Life Sciences has also received several federal grants to advance its research and development efforts. The company was awarded a $295,386 grant from NIAID to develop and evaluate a vaccine candidate against urogenital schistosomiasis, building on its prior work with the "SchistoShield" vaccine. Another NIAID grant of $600,000 supports the evaluation of next-generation schistosomiasis vaccine candidates, including a redesigned SM-P80 antigen and self-replicating RNA vaccines using a lipid inorganic nanoparticle delivery platform. PAI Life Sciences also received a $243,000 grant from the Centers for Disease Control and Prevention to develop adjuvanted recombinant candidates to prime and boost COVID-19 RNA vaccines. Additionally, the company was granted funding to develop a screen for new adjuvants to enhance RNA vaccines, further demonstrating its commitment to advancing vaccine technology across multiple infectious disease areas.
Quick answers
What is PAI Life Sciences Inc.'s UEI?
PAI Life Sciences Inc.'s Unique Entity ID (UEI) in SAM.gov is MSMLUCM9DRT6.
What is PAI Life Sciences Inc.'s CAGE code?
PAI Life Sciences Inc.'s CAGE code is 47SX4.
What is PAI Life Sciences Inc.'s primary NAICS code?
PAI Life Sciences Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is PAI Life Sciences Inc. located?
PAI Life Sciences Inc.'s physical address in SAM.gov is 1551 Eastlake Ave E #250, Seattle, WA 98102, USA.
Is PAI Life Sciences Inc. registered in SAM.gov?
Yes. PAI Life Sciences Inc.'s SAM.gov registration is active through May 29, 2027.
What is PAI Life Sciences Inc.'s most recent federal award?
PAI Life Sciences Inc.'s most recent federal grant award is Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, hematoshield - project summary… (R41AI181069), from National Institute of Allergy and Infectious Diseases, on January 3, 2024.
On GovTribe
See PAI Life Sciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors